| Study period | ||||||||
---|---|---|---|---|---|---|---|---|---|
Enrolment/allocation | Post-allocation | Close-out | |||||||
Outpatient clinics | Neoadjuvant treatment | CRS-HIPEC | Adjuvant treatment | 3 months after CRS-HIPEC | 6 months after CRS-HIPEC | 9 months after CRS-HIPEC | Every 6 months | 5 years after randomisation | |
Enrolment/allocation | |||||||||
 Eligibility screen | X |  |  |  |  |  |  |  |  |
 Informed consent | X |  |  |  |  |  |  |  |  |
 Allocation | X |  |  |  |  |  |  |  |  |
Interventions | |||||||||
 Chemotherapy |  | X |  | X |  |  |  |  |  |
 Bevacizumab |  | Xa |  |  |  |  |  |  |  |
 CRS-HIPEC |  |  | X |  |  |  |  |  |  |
 Thoracoabdominal CT |  | Xb |  |  | X |  | X | X | X |
 Questionnaires | X | Xc |  |  | X | X | X | X | X |
 Translational research: blood | X | Xd | Xe | Xd | X |  | X | X | X |
 Translational research: tissue |  |  | X |  |  |  |  |  |  |
Assessments | |||||||||
 Baseline characteristics | X |  |  |  |  |  |  |  |  |
 Feasibility of systemic therapy |  | X | X | X |  |  |  |  |  |
 Safety/toxicity of systemic therapy |  | X | X | X |  |  |  |  |  |
 Radiological response |  | X |  |  |  |  |  |  |  |
 Histopathological response |  |  | X |  |  |  |  |  |  |
 Surgical characteristics |  |  | X |  |  |  |  |  |  |
 Postoperative morbidity |  |  | X |  | X |  |  |  |  |
 Progression-free survival |  | X | X | X | X | X | X | X | X |
 Disease-free survival |  |  | X | X | X | X | X | X | X |
 Overall survival |  | X | X | X | X | X | X | X | X |
 Health-related quality of life | X | X | X |  | X | X | X | X | X |
 Costs | X | X | X |  | X | X | X | X | X |